Amgen (AMGN) calls more active than puts, call put ratio 1.4 calls to 1 put into Q2

Go back to Amgen (AMGN) calls more active than puts, call put ratio 1.4 calls to 1 put into Q2

Amgen (AMGN) PT Raised to $180 at UBS Following Solid 2Q

July 26, 2017 8:34 AM EDT

UBS raised its price target on Amgen (NASDAQ: AMGN) to $180.00 (from $175.00) while maintaining a Neutral rating. 2Q results were better than expectations with a $145M top-line beat. EPS also beat consensus estimates by $0.18.

UBS increased 2017 Enbrel sales estimates to $5.38B from $5B... More